MANGALAM2023-10-012023-12-31 MANGALAM2023-10-012023-12-31 MANGALAM2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member MANGALAM2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member MANGALAM2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532637 MANGALAM NOTLISTED Mangalam Drugs And Organics Limited Equity 2023-04-01 2024-03-31 2024-02-13 2024-02-06 INR Lakhs Third quarter 16:30:00 19:30:00 2024-02-13 2024-02-13 Not applicable Single segment Manufacturing of Bulk Drugs 2023-10-01 2023-12-31 Unaudited Standalone 973360000.00 19000.00 973379000.00 466480000.00 19890000.00 206281000.00 89712000.00 33095000.00 36239000.00 121242000.00 972939000.00 440000.00 0.00 440000.00 -1061000.00 -3500000.00 -4561000.00 0.00 5001000.00 0.00 0.00 0.00 0.00 5001000.00 312000.00 5313000.00 0.00 0.00 158282000.00 10 0.32 0.32 0.00 0.00 0.32 0.32 0.00 0.00 0.00 1.The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. 2.The above Unaudited financial results of the (Company) Mangalam Drugs and Organics Limited for the quarter and nine months ended 31st December 2023 have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company at their meeting held on 13 th February , 2024 3.The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. 4.The figures for the quarter ended 31st December, 2023 are the balancing figures between the figures in respect of the nine months ended 31st December 2023 and the unaudited published figures for half year ended 30th September 2023 5.The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation. 6.As on september 30 ,2023 , the Company has acquired 3010 equity shares of Rs. 100/- each from the shareholders of Mangalam Laboratories Private Limited (MLPL)which is into the business of manufacturing & trading of pharmaceutical products. On acquisition MLPL has become a wholly owned subsidiary of the Company but is not a material subsidiary. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 2663595000.00 504000.00 2664099000.00 1732054000.00 26333000.00 100161000.00 279648000.00 99662000.00 107726000.00 468466000.00 2814050000.00 -149951000.00 0.00 -149951000.00 0.00 -24000000.00 -24000000.00 0.00 -125951000.00 0.00 0.00 0.00 0.00 -125951000.00 936000.00 -125015000.00 0.00 0.00 158282000.00 10 -7.96 -7.96 0.00 0.00 -7.96 -7.96 0.00 0.00 0.00 Other Expenses 121242000.00 Other Expenses 468466000.00 312000.00 936000.00 0.00 0.00 0.00 0.00